BioPorto (CPSE:BIOPOR) - Share price, News & Analysis

BIOPOR fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

BIOPOR Stock Overview

BioPorto A/S, an in-vitro diagnostics company, provides diagnostic tests and antibodies to clinicians and researchers worldwide.

Rewards

Revenue is forecast to grow 23.02% per year

Risk Analysis

Earnings are forecast to decline by an average of 16.3% per year for the next 3 years

Has less than 1 year of cash runway

Currently unprofitable and not forecast to become profitable over the next 3 years

Volatile share price over the past 3 months

+ 3 more risks

BioPorto Competitors

Bavarian Nordic

CPSE:BAVA

kr.14.4b

Emergent BioSolutions

NYSE:EBS

US$1.7b

Chimerix

NasdaqGM:CMRX

US$156.5m

Price History & Performance

Summary of all time highs, changes and price drops for BioPorto
Historical stock prices
Current Share Price	kr.1.25
52 Week High	kr.4.10
52 Week Low	kr.1.14
Beta	1.2
1 Month Change	-3.55%
3 Month Change	-35.34%
1 Year Change	-61.60%
3 Year Change	-68.56%
5 Year Change	-53.26%
Change since IPO	-99.46%

Shareholder Returns

	BIOPOR	DK Biotechs	DK Market
7D	6.5%	2.5%	0.2%
1Y	-61.6%	-17.0%	1.0%

Return vs Industry: BIOPOR underperformed the Danish Biotechs industry which returned -17% over the past year.

Return vs Market: BIOPOR underperformed the Danish Market which returned 1% over the past year.

Price Volatility

Is BIOPOR's price volatile compared to industry and market?
BIOPOR volatility
BIOPOR Average Weekly Movement	10.6%
Biotechs Industry Average Movement	8.1%
Market Average Movement	6.3%
10% most volatile stocks in DK Market	10.7%
10% least volatile stocks in DK Market	3.8%

Stable Share Price: BIOPOR is more volatile than 75% of Danish stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: BIOPOR's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of Danish stocks.

About the Company

Founded	Employees	CEO	Website
2000	29	Tony Pare	https://bioporto.com

BioPorto A/S, an in-vitro diagnostics company, provides diagnostic tests and antibodies to clinicians and researchers worldwide. The company offers the neutrophil gelatinase-associated lipocalin test, a particle-enhanced turbidimetric test that measures NGAL that is used to supplement clinical evaluation and standard tests; monoclonal antibodies for scientific, pharmaceutical, and clinical research use; enzyme-linked immunosorbent assay kits; IVD automated assays; and generic rapid assay device platform for the development of lateral flow assays. It sells its products through own sales team, distributors, and OEM partnerships.

BioPorto Fundamentals Summary

How do BioPorto's earnings and revenue compare to its market cap?
BIOPOR fundamental statistics
Market Cap	kr.417.68m
Earnings (TTM)	-kr.57.11m
Revenue (TTM)	kr.24.25m

17.2x

P/S Ratio

-7.3x

P/E Ratio

Is BIOPOR overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
BIOPOR income statement (TTM)
Revenue	kr.24.25m
Cost of Revenue	kr.9.21m
Gross Profit	kr.15.04m
Other Expenses	kr.72.15m
Earnings	-kr.57.11m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

Aug 17, 2022

Earnings per share (EPS)	-0.17
Gross Margin	62.01%
Net Profit Margin	-235.48%
Debt/Equity Ratio	0%

How did BIOPOR perform over the long term?

See historical performance and comparison

Valuation

Is BioPorto undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

9.09x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate BIOPOR's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate BIOPOR's fair value for valuation analysis.

Price To Earnings Ratio

PE vs Industry: BIOPOR is unprofitable, so we can't compare its Price-To-Earnings Ratio to the European Biotechs industry average.

PE vs Market: BIOPOR is unprofitable, so we can't compare its Price-To-Earnings Ratio to the Danish market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BIOPOR's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: BIOPOR is overvalued based on its Price-To-Book Ratio (9.1x) compared to the DK Biotechs industry average (5.6x).

Future Growth

How is BioPorto forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

-16.3%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: BIOPOR is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: BIOPOR is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: BIOPOR is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: BIOPOR's revenue (23% per year) is forecast to grow faster than the Danish market (5.9% per year).

High Growth Revenue: BIOPOR's revenue (23% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if BIOPOR's Return on Equity is forecast to be high in 3 years time

Past Performance

How has BioPorto performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-18.5%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: BIOPOR is currently unprofitable.

Growing Profit Margin: BIOPOR is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: BIOPOR is unprofitable, and losses have increased over the past 5 years at a rate of 18.5% per year.

Accelerating Growth: Unable to compare BIOPOR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BIOPOR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-6.2%).

Return on Equity

High ROE: BIOPOR has a negative Return on Equity (-124.26%), as it is currently unprofitable.

Financial Health

How is BioPorto's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: BIOPOR's short term assets (DKK64.2M) exceed its short term liabilities (DKK24.8M).

Long Term Liabilities: BIOPOR's short term assets (DKK64.2M) exceed its long term liabilities (DKK10.5M).

Debt to Equity History and Analysis

Debt Level: BIOPOR is debt free.

Reducing Debt: BIOPOR has not had any debt for past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BIOPOR has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: BIOPOR has less than a year of cash runway if free cash flow continues to reduce at historical rates of 18.6% each year

Dividend

What is BioPorto current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate BIOPOR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BIOPOR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BIOPOR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BIOPOR's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as BIOPOR has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

0.5yrs

Average management tenure

CEO

Tony Pare (58 yo)

0.50

Tenure

Mr. Anthony P. Pare, also known as Tony, serves as Chief Executive Officer of BioPorto A/S since November 2021. He served as Chief Commercial Officer at T2 Biosystems, Inc. since January 08, 2020. He serve...

Leadership Team

Experienced Management: BIOPOR's management team is not considered experienced ( 0.5 years average tenure), which suggests a new team.

Board Members

Experienced Board: BIOPOR's board of directors are considered experienced (5.5 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 25%.

Data	Last Updated (UTC time)
Company Analysis	2022/05/26 00:00
End of Day Share Price	2022/05/25 00:00
Earnings	2021/12/31
Annual Earnings	2021/12/31